ESTRO 2022 - Abstract Book

S1240

Abstract book

ESTRO 2022

Conclusion Maximum dose to the esophagus was significantly lower in the interventional arm at the cost PTV as well as GTV coverage. A passus, that allows the treating physician to violate the esophagus constraint if GTV V 90% < 94%, is amended to the trial protocol.

PO-1461 Retrospective comparison of two radiotherapy schedules for spinal cord compression

M. Hernández Miguel 1 , B. Gil Haro 1 , M. López Valcárcel 1 , R. Benlloch Rodríguez 1 , J. Velasco Jiménez 1 , S. Córdoba Largo 1 , C. de la Fuente Alonso 1 , O. Engel 1 , A. Valcárcel Díaz 1 , L. Paisán Palacio 1 , S. Santana Jiménez 1 , P. Sarrión Rubio de la Torre 1 , S. Pérez Mata 1 , F.J. Martínez Paredes 1 , J. Romero Fernández 1

1 University Hospital Puerta de Hierro, Radiation Oncology, Madrid, Spain

Purpose or Objective To compare improvement in pain, spinal cord compression (SCC) signs and overall survival (OS) between two common radiotherapy schedules: 20Gy in 5 fractions (RT20) and 30Gy in 10 fractions (RT30). Materials and Methods From January 2016 to December 2020, 180 patients (p) with radiological or clinical SCC were treated. Clinical characteristics: 112 males (62.2%) and 68 females (37.8%); median age: 65 years (range 35-90). The most common primary tumours were lung (60p), breast (35p) and prostate cancer (30p). Thoracic spine was the location most frequent (148p; 82.8%) followed by lumbar spine (55p; 30.6%) and cervical spine (28p; 15.6%). Most patients were treated with RT20 (86p) or RT30 (87p). All patients were treated within 24h from the radiological diagnosis by MRI. Statistics: Student´s T test, chi- square and Kaplan Meier. Results One hundred and fifty-one patients presented symptoms or SCC signs (83.9%). Pain was the most common (150p; 83.3%) followed by motor deficits (41p; 22.8%), sensory deficits (21p; 11.7%) and autonomic dysfunction (2p; 1.1%). Radiotherapy significantly improves pain (mean Visual Analog Scale of 7.13 vs 3.24 before and after treatment, respectively; p<0.001). There were no differences in pain relief or recovery from SCC signs between RT20 and RT30 schedules. Two-year OS was better in breast cancer patients (33% vs 17.5% and 9.4% for prostate and lung cancer, respectively; p=0.001). A better OS was observed for the RT30 schedule (23.9% vs 7.5% for RT20; p<0.001).